Dara-CVRd as Induction and Extended Consolidation Improves Outcomes in Patients With Ultra–High-Risk Multiple Myeloma
Written by Rafael Fonseca MD
Related Articles
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Read it now on PracticeUpdate.com
Mexico’s Irresponsible Populist President Proposes Election-Year Giveaway
I’ve written many columns about Venezuela, Chile, and Argentina, but only one column specifically about Mexico. Since I’m currently in Mexico City doing some meetings…
Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy
Radiation therapy (RT) may play an important role prior to and following BCMA-targeted CAR T-cell therapy in multiple myeloma (MM). We report a series…
Genomic Classification and Individualized Prognosis in Multiple Myeloma
Read it now on PracticeUpdate.com
Genomic Classification and Individualized Prognosis in Multiple Myeloma
Read it now on PracticeUpdate.com
Incidence or T cell lymphoma in patients diagnosed with multiple myeloma or diffuse large B-cell lymphoma
A Komodo Real World Evidence analysis
Incidence or T cell lymphoma in patients diagnosed with multiple myeloma or diffuse large B-cell lymphoma
A Komodo Real World Evidence analysis
Incidence or T cell lymphoma in patients diagnosed with multiple myeloma or diffuse large B-cell lymphoma
A Komodo Real World Evidence analysis
Real-World Clinical Equivalence of Generic and Branded Tofacitinib: A Prospective Longitudinal Cohort Study in Patients With Rheumatoid Arthritis
To explore the clinical efficacy and safety of generic tofacitinib vs brand name tofacitinib in patients with rheumatoid arthritis (RA) in a single-ce…